Prevention of Retinochoroiditis in Congenital Toxoplasmosis Europe Versus South America

Ligia Alejandra Delatorre Cifuentes, Arnaud Sauer, Jorge Enrique Gomez-Marin, Tristan Bourcier, Justus Garweg, Claude Speeg-Schatz, Ermanno Candolfi

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Congenital toxoplasmosis is suspected when seroconversion occurs in a pregnant woman, and it
is confirmed by one or more biologic tests (polymerase chain reaction on amniotic fluid or
neonatal serodiagnosis). The methods used are diagnostic in more than 95% of cases at birth and in
100% of cases by the age of 9 months.1 Ocular lesions represent the most frequent complication of
congenital toxoplasmosis, independent of any treatment.2 The risk of toxoplasmic retinochoroiditis
is highly unpredictable, however, mainly because the pathophysiology is poorly understood.3 By
school age, 10% to 20% of children with congenital toxoplasmosis have one or more retinochoroidal
lesions, but more than 90% of them have normal vision in both eyes; bilateral blindness is very
rare.4–6 This article focuses on the controversy surrounding the effectiveness of screening and
treatment for children with congenital toxoplasmosis.
Translated title of the contributionPrevención de Retinochoroiditis en Toxoplasmosis Congénita Europa Versus América del Sur
Original languageEnglish
Pages (from-to)601-603
Number of pages3
JournalPediatric Infectious Disease Journal
Issue number7
StatePublished - Jul 2011


Dive into the research topics of 'Prevention of Retinochoroiditis in Congenital Toxoplasmosis Europe Versus South America'. Together they form a unique fingerprint.

Cite this